ORUM THERAPEUTICS
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibody therapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.
ORUM THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Daejeon, Taejon-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.orumrx.com
Total Employee:
11+
Status:
Active
Total Funding:
92 M USD
Technology used in webpage:
Viewport Meta Google Analytics Google Tag Manager Content Delivery Network Global Site Tag IPv6 Google Typekit Squarespace
Current Advisors List
Board_member
Board_member
2019-05-01
Current Employees Featured
Jaewon Kim Chief Financial Officer @ Orum Therapeutics
Chief Financial Officer
Olaf Christensen Chief Medical Officer @ Orum Therapeutics
Chief Medical Officer
2021-10-01
Yong Sung KIM, Scientific &Co- Founder @ Orum Therapeutics
Scientific &Co- Founder
Peter U. Park Chief Scientific Officer @ Orum Therapeutics
Chief Scientific Officer
2019-01-01
Sung Joo LEE CEO & Founder @ Orum Therapeutics
CEO & Founder
2016-08-01
Founder
Investors List
IMM Investment
IMM Investment investment in Series B - Orum Therapeutics
Atinum Investment
Atinum Investment investment in Series B - Orum Therapeutics
KB Investment
KB Investment investment in Series B - Orum Therapeutics
KDB Capital
KDB Capital investment in Series B - Orum Therapeutics
KB Investment
KB Investment investment in Series B - Orum Therapeutics
InterVest
InterVest investment in Series B - Orum Therapeutics
Smilegate Investment
Smilegate Investment investment in Series B - Orum Therapeutics
KTB Network
KTB Network investment in Series B - Orum Therapeutics
Solidus Investment
Solidus Investment investment in Series B - Orum Therapeutics
ST Asset Management
ST Asset Management investment in Series B - Orum Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-06 | Orum Therapeutics Appoints Olaf Christensen, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.orumrx.com Semrush global rank: 4.9 M Semrush visits lastest month: 1.78 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Orum Therapeutics"
Investors Home — Orum Therapeutics - orumrx.com
Our company exists to cure cancer patients and beyond, through innovative research and development of therapeutics and technologies. We aim to succeed by maintaining our …See details»
Orum Therapeutics
TPD² Cell Selective Degradation . Our breakthrough protein degrader approach is designed to improve upon efficacy, safety, and half-life of conventional targeted protein degradersSee details»
Orum Therapeutics - Crunchbase Company Profile & Funding
ORM-5029: A targeted protein degradation therapy for HER2-expressing breast cancer, currently in Phase 1 clinical trial. ORM-6151: A CD33-antibody enabled GSPT1 degrader for the …See details»
Orum Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Contacts Corporate: Kayla (Gyebang) Mo, Director, IR/PR, Orum Therapeutics, media@orumrx.com Media: Jessica Yingling, Ph.D., President, Little Dog Communications …See details»
Careers - Orum Therapeutics
“At Orum, we are laser focused on bringing cutting edge science to the patient to make fundamental changes in their lifes. By combining the new field of targeted protein degradation …See details»
Orum Therapeutics Announces a Global, Multi-Target License and …
Jul 16, 2024 BOSTON & DAEJEON, South Korea, July 16, 2024--A Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel …See details»
Orum Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Orum Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer
May 26, 2021 Contacts. Corporate: Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics, +82-42-716-3030, contact@orumrx.com Media: Jessica Yingling, Ph.D., …See details»
투자기업 – 투자기업 – 카이트창업가재단
홈페이지 www.orumrx.com 회사소개 오름테라퓨틱㈜은 항체기반 플랫폼을 개발해 기존의 합성신약 또는 항체기술로 표적이 어려운 난치병을 유발하는 세포 내 바이오 분자를 효과적으로 공략할 수 …See details»
Orum Therapeutics - VentureRadar
"Orum Therapeutics is a private biotech company located in Daejeon, Korea and Cambridge, Massachusetts. We are developing a novel class of therapeutic antibodies to bring new …See details»
Orum Therapeutics - Employees, Contact info, Overview - Wiza
Apr 30, 2024 View info about Orum Therapeutics (orumrx.com). Orum Therapeutics is a company located in Cambridge, Massachusetts, United States. Find employees, official …See details»
Orum Therapeutics, Inc. (Orum Therapeutics, Inc.) - 药物管线_专 …
了解Orum Therapeutics, Inc. (Orum Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 39篇新闻和3篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，技术平台:小 …See details»
Significant Shareholding Disclosure Report — Orum Therapeutics
Feb 28, 2025 Significant Shareholding Disclosure Report - KR / EN. Sophia (Sujin) Kim. PreviousSee details»
Orum Therapeutics Presents Preclinical Data at AACR 2022 …
Apr 8, 2022 The poster is available on request; please email us at contact@orumrx.com. About Orum’s AnDC Platform. Orum’s Antibody neoDegrader Conjugate (AnDC™) platform uses the …See details»
Orum Therapeutics USA, Inc. (Orum Therapeutics USA, Inc.) - 药物 …
了解Orum Therapeutics USA, Inc. (Orum Therapeutics USA, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试，疾病领域:肿瘤，技术平台:定向降解抗体偶联物，药物:ORM …See details»
Orum Therapeutics Presents Positive Preclinical Data of ORM …
Dec 10, 2022 BOSTON, MA, USA & DAEJEON, South Korea I December 10, 2022 IOrum Therapeutics, a private biotechnology company pioneering the development of tumor-directed …See details»
Pipeline and Partnerships — Orum Therapeutics
In November 2023, Bristol Myers Squibb acquired ORM-6151/BMS-986497 at a total deal value of $180 million. ORM-6151/BMS-986497 is a first-in-class, anti-CD33 antibody-enabled GSPT1 …See details»
Wave of Antibody-Drug Conjugates Poised to Change Treatment …
May 29, 2024 The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) …See details»
Orum Therapeutics Submits Registration Statement for KOSDAQ …
Oct 2, 2024 DAEJEON, South Korea & BOSTON, October 02, 2024--Orum Therapeutics Submits Registration Statement for KOSDAQ ListingSee details»
Optum Rx to Modernize Pharmacy Payment Models
3 days ago Epic Pharmacy Network, Inc. (EPN), a Pharmacy Services Administrative Organization representing over 1,000 independent pharmacies across the U.S., has partnered …See details»